David J. Arthur - Jan 20, 2022 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fac
Stock symbol
SLRX
Transactions as of
Jan 20, 2022
Transactions value $
$0
Form type
4
Date filed
1/21/2022, 03:08 PM
Previous filing
Nov 5, 2021
Next filing
Mar 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRX Stock Option (right to buy) Award $0 +500K $0.00 500K Jan 20, 2022 Common Stock 500K $0.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options are fully vested on January 19, 2023, and 1/36 of the remaining options vest on each monthly anniversary thereafter.